Summary
Combining ampicillin with an irreversible β- lactamase inhibitor such as sulbactam is a promising technique for controlling infections due to resistant organisms. The combination not only restores the effectiveness of ampicillin against species that have acquired resistance to it, but it can extend the antimicrobial spectrum to species that have never exhibited susceptibility to ampicillin.
However, the inhibition of β- lactamases and the evaluation of inhibitors are still complicated by numerous factors known collectively as ‘the epidemiology of β- lactamases’. This refers to the distribution of enzymes in different bacterial species and in different geographical locations, the numerous types of enzymes, the variable number and amount of β- lactamases that may exist in the same cell, and, of course, the potential for transfer of β- lactamase resistance from one species to another.
Similar content being viewed by others
References
Acar JF, Minozzi C. Role of β-laclamases in the resistance of gram-negative bacilli to β-lactam antibiotics. Review of Infectious Diseases 8 (Suppl. 5): S482–S486. 1986
Arisawa M. Then RL. 6 Acetylmethylene-penicillanic acid (Ro 15-1903), a potent β-laclamase inhibitor. I. Inhibition of chromosomally and R-factor mediated β-lactamases. Journal of Antibiotics 35: 1578–1583. 1982
Bush K. Sykes RB. β-Lactamase inhibitors in perspective. Journal of Antimicrobial Chemotherapy 11: 97–107. 1983
Eley A, Greenwod D. Characterization of β-lactamases in clinical isolates of bacteroides. Journal of Antimicrobial Chemotherapy 18: 325–333, 1986
Kitzis MD, Goldstein FW, Labia R. Acar JF. Activité du sulbactam et de l’acide clavulanique, seuls ou associés, sur Acinelobacter calcoaceticus. Annals of Microbiology (Institut Pasteur) 134A: 163–168, 1983
Medeiros AA. β-Lactamases. British Medical Bulletin 40: 18–27, 1984
Philippon A. Paul G. Nevot P. Mécanisme de résistance enzymatique aux β-laclamines. Presse Médicale 46: 2290–2296. 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Acar, J.F., Gutmann, L. & Kitzis, MD. β-Lactamases in Clinical Isolates Spectrum Implications of Sulbactam/Ampicillin. Drugs 35 (Suppl 7), 12–16 (1988). https://doi.org/10.2165/00003495-198800357-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198800357-00004